Search Follow us

Mologen (MGN)

Business description

Mologen is a German biotech company developing cancer immunotherapies. The lead product is lefitolimod (MGN1703) for metastatic colorectal cancer maintenance, SCLC and HIV. Development of MGN1601, a therapeutic renal cell vaccine, would be reinitiated on successful out-licensing of lefitolimod.

MGN1703 leading the way

Update | Pharmaceutical & healthcare | 20/08/2015

Mologen’s lead product, MGN1703, is currently in three clinical trials for different indications. The €28.3m (gross) proceeds from the rights issue in April 2015 mean Mologen should have sufficient funds to reach full recruitment of IMPALA (Phase III in colorectal cancer) and top-line data from IMPULSE (Phase II in small-cell lung cancer). The IMPULSE data (H216) could have a positive impact on partnering or financing options for MGN1703. We value Mologen at €384m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€34.6m
Last close€0.919
High / Low (52 weeks)€3.9 / €0.9
Stock market listingDE
Forecast net debt (€m)8.2
Forecast gearing ratio (%)58
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(1.2)(52.5)(76.3)
Relative *3.5(54.3)(75.9)

* % Relative to local index

Company news